Prolotherapy Injection: Difference between revisions

From WikiMSK

No edit summary
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{stub}}
{{stub}}
See Hauser et al for a free open access systematic review from 2016. <ref>{{#pmid:27429562}}</ref>
{{Controversial}}
See Hauser et al for a free open access systematic review from 2016.<ref>{{#pmid:27429562}}</ref>The most commonly use agent is dextrose usually in concentrations between 5-20%. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.
 
== Articles ==
{{PDF|Fullerton2018.pdf|Prolotherapy for the thoracolumbar fascia - Fullerton 2018}}


==References==
==References==

Latest revision as of 16:10, 26 March 2022

This article is a stub.
This page or section deals with a controversial topic.
Please use your clinical judgement.

See Hauser et al for a free open access systematic review from 2016.[1]The most commonly use agent is dextrose usually in concentrations between 5-20%. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.

Articles

References

  1. Hauser et al.. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clinical medicine insights. Arthritis and musculoskeletal disorders 2016. 9:139-59. PMID: 27429562. DOI. Full Text.

Literature Review